EGFR and neoplasm: The analysis of the subsequent studies confirmed that, in Asian countries, EGFR mutations were found in about half of patients with LUAD, while in western countries, the percentage of EGFR mutations was around 10%; accordingly, the rates of non-smokers among EGFR-positive NSCLC patients were significantly higher than in patients with EGFR wild-type tumours [8].